Detection of antibodies against SARS-CoV-2 spike protein by gold nanospikes in an opto-microfluidic chip
Detection of antibodies against SARS-CoV-2 spike protein by gold nanospikes in an opto-microfluidic chip
复制标题
DOI：
10.1016/j.bios.2020.112578
复制
发表时间：
2020-12-01
影响因子：
12.6
通讯作者：
Shen, Amy Q.
中科院分区：
文献类型：
--
作者：
Funari, Riccardo;Chu, Kang-Yu;Shen, Amy Q.
严重急性呼吸道综合征冠状病毒2（SARS-CoV-2）的全球大流行引发了对其相关诊断和医疗的积极研究。虽然定量逆转录聚合酶链反应（qRT-PCR）是检测SARS-CoV-2病毒基因的最可靠方法，但特异性抗病毒抗体的血清学检测也很重要，因为它们可以识别假阴性qRT-PCR反应，跟踪患者免疫系统对抗感染的有效性，并可能有助于血浆输注治疗。在这项工作中，基于局域表面等离子体共振（LSPR）的原理，我们开发了一种具有金纳米刺的光微流控传感平台，通过电沉积制备，用于检测1 μ L稀释于1 mL缓冲溶液中的人血浆中SARS-CoV-2刺突蛋白特异性抗体的存在和量，目标抗体浓度可以与抗原抗体结合引起的局部折射率变化引起的金纳米钉的LSPR波长峰位移相关。这种无标记的微流体平台实现了类似于0.08 ng/mL（类似于0.5 pM）的检测限，落在临床相关浓度范围内。我们证明，我们的光微流控平台提供了一个有前途的即时检测工具，以补充标准血清学检测，并使SARS-CoV-2定量诊断更容易，更便宜，更快。
The ongoing global pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to active research in its associated diagnostics and medical treatments. While quantitative reverse transcription polymerase chain reaction (qRT-PCR) is the most reliable method to detect viral genes of SARS-CoV-2, serological tests for specific antiviral antibodies are also important as they identify false negative qRT-PCR responses, track how effectively the patient's immune system is fighting the infection, and are potentially helpful for plasma transfusion therapies. In this work, based on the principle of localized surface plasmon resonance (LSPR), we develop an opto-microfluidic sensing platform with gold nanospikes, fabricated by electrodeposition, to detect the presence and amount of antibodies specific to the SARS-CoV-2 spike protein in 1 mu L of human plasma diluted in 1 mL of buffer solution, within similar to 30 min. The target antibody concentration can be correlated with the LSPR wavelength peak shift of gold nanospikes caused by the local refractive index change due to the antigen-antibody binding. This label-free microfluidic platform achieves a limit of detection of similar to 0.08 ng/mL (similar to 0.5 pM), falling under the clinical relevant concentration range. We demonstrate that our opto-microfluidic platform offers a promising point-of-care testing tool to complement standard serological assays and make SARS-CoV-2 quantitative diagnostics easier, cheaper, and faster.